Viral Hemorrhagic Fever Vaccines Pipeline
Pipeline
Viral hemorrhagic fevers are caused by several families of viruses. The disease caused by these viruses affect multiple organ systems, often damaging the overall vascular system and impairing the body’s ability to regulate itself. These symptoms are often accompanied by bleeding. Many of these viruses cause severe, life-threatening disease.
Ebola Virus
Crimean-Congo Hemorrhagic Fever Virus
Ebola Virus
We are using our ability to construct highly valid recombinant proteins to address Filovirus with two approaches. The Company has developed and patented recombinant proteins from Ebola Zaire, Ebola Sudan, and Marburg virus.
These proteins are being developed into both individual vaccines and a multivalent Filovirus vaccine. Furthermore, under license from the Company, researchers at the University of Hawaii School of Medicine are working to develop a thermal-stable Ebola vaccine suitable for worldwide distribution without a cold chain requirement. Non-human primate studies have confirmed the efficacy of our approach.
Crimean-Congo Hemorrhagic Fever Virus
Infectious agents that pose the greatest threat are those that are highly infectious, have high rates of mortality and lack any approved treatments. Crimean-Congo hemorrhagic fever virus (CCHFV), genus Nairovirus, family Bunyaviridae, is one such pathogen. CCHFV is a highly infectious virus, with mortality rates as high as 50%.
CCHFV’s natural geographic distribution continues to expand and whose highly pathogenic characteristics and potential to spread through various mechanisms make it a serious threat, whether through a natural outbreak or bioterrorism. CCHFV is classified as a biosafety level-4 (BSL-4) pathogen and has been recently reclassified as a Category A Priority Pathogen by NIH. This elevated level of priority for CCHFV is due to its highly infectious nature and recent reports of transmission by aerosol during the treatment of infected patients.
Hawaii Biotech is developing a CCHF vaccine utilizing our proprietary vaccine development platform. The goal of this program is to develop a safe vaccine demonstrating robust, protective immunity. Hawaii Biotech collaborates with the University of Texas Medical Branch to achieve our development objectives.
Ebola Virus
Ebola Virus
We are using our ability to construct highly valid recombinant proteins to address Filovirus with two approaches. The Company has developed and patented recombinant proteins from Ebola Zaire, Ebola Sudan, and Marburg virus.
These proteins are being developed into both individual vaccines and a multivalent Filovirus vaccine. Furthermore, under license from the Company, researchers at the University of Hawaii School of Medicine are working to develop a thermal-stable Ebola vaccine suitable for worldwide distribution without a cold chain requirement. Non-human primate studies have confirmed the efficacy of our approach.
Crimean-Congo Hemorrhagic Fever Virus
Crimean-Congo Hemorrhagic Fever Virus
Infectious agents that pose the greatest threat are those that are highly infectious, have high rates of mortality and lack any approved treatments. Crimean-Congo hemorrhagic fever virus (CCHFV), genus Nairovirus, family Bunyaviridae, is one such pathogen. CCHFV is a highly infectious virus, with mortality rates as high as 50%.
CCHFV’s natural geographic distribution continues to expand and whose highly pathogenic characteristics and potential to spread through various mechanisms make it a serious threat, whether through a natural outbreak or bioterrorism. CCHFV is classified as a biosafety level-4 (BSL-4) pathogen and has been recently reclassified as a Category A Priority Pathogen by NIH. This elevated level of priority for CCHFV is due to its highly infectious nature and recent reports of transmission by aerosol during the treatment of infected patients.
Hawaii Biotech is developing a CCHF vaccine utilizing our proprietary vaccine development platform. The goal of this program is to develop a safe vaccine demonstrating robust, protective immunity. Hawaii Biotech collaborates with the University of Texas Medical Branch to achieve our development objectives.
